1588 related articles for article (PubMed ID: 34399090)
1. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study.
Laxminarayan R; B CM; G VT; Arjun Kumar KV; Wahl B; Lewnard JA
Lancet Infect Dis; 2021 Dec; 21(12):1665-1676. PubMed ID: 34399090
[TBL] [Abstract][Full Text] [Related]
2. All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study.
Lewnard JA; Mahmud A; Narayan T; Wahl B; Selvavinayagam TS; Mohan B C; Laxminarayan R
Lancet Infect Dis; 2022 Apr; 22(4):463-472. PubMed ID: 34953536
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
6. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
7. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
[TBL] [Abstract][Full Text] [Related]
8. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
COVID-19 Forecasting Team
Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
[TBL] [Abstract][Full Text] [Related]
9. Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020.
; ; ;
Indian J Med Res; 2020 May; 151(5):424-437. PubMed ID: 32611914
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
13. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
14. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
16. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
17. Representative estimates of COVID-19 infection fatality rates from four locations in India: cross-sectional study.
Cai R; Novosad P; Tandel V; Asher S; Malani A
BMJ Open; 2021 Oct; 11(10):e050920. PubMed ID: 34610940
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.
Wagner R; Peterhoff D; Beileke S; Günther F; Berr M; Einhauser S; Schütz A; Niller HH; Steininger P; Knöll A; Tenbusch M; Maier C; Korn K; Stark KJ; Gessner A; Burkhardt R; Kabesch M; Schedl H; Küchenhoff H; Pfahlberg AB; Heid IM; Gefeller O; Überla K
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200766
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
